期刊文献+

关注小肠移植预防排斥反应的新措施 被引量:1

原文传递
导出
摘要 经过近20多年的发展,小肠移植已成为治疗常规手段无法治愈的小肠疾病的理想方法。目前,在全球领先的小肠移植中心,受者的1年和2年存活率分别可达90%和80%,这固然与小肠移植外科技术、适应证选择、围手术期处理、排斥反应监测、感染防治及促进移植肠功能恢复等主要技术进步有关,但小肠是一个高度免疫原性器官,移植肠的排斥反应是小肠移植成功的最主要障碍,因而预防排斥反应的措施,如免疫抑制方案及理念的改进在小肠移植的整个环节中占据了最重要的位置。本文就小肠移植中相关免疫抑制方案的变化,以及更为重要的新治疗理念进行如下综述。
作者 李元新
机构地区 解放军第三
出处 《中华器官移植杂志》 CAS CSCD 北大核心 2012年第7期441-443,共3页 Chinese Journal of Organ Transplantation
  • 相关文献

参考文献8

二级参考文献95

  • 1李宁,黎介寿,李幼生,江志伟,尹路,张利华,任建安,舒志军.我国首例异体小肠移植成功的临床经验[J].解放军医学杂志,1994,19(4):252-254. 被引量:17
  • 2李元新,李宁.短肠综合征治疗中值得注意的问题[J].中国实用外科杂志,2005,25(11):649-651. 被引量:6
  • 3侵袭性肺部真菌感染的诊断标准与治疗原则(草案)[J].中华内科杂志,2006,45(8):697-700. 被引量:869
  • 4The US: Organ procurement and transplantation network and the scientific registry of transplant recipients. The 2007 OPTN/SRTR annual report : transplant data 1997 - 2006 [ M/OL ]. http :// www. optn, org. 2008,6. 被引量:1
  • 5Watson CJE, Bradley JA, Friend PJ, et al. Alemtuzumab ( CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years[ J]. Am J Transplant,2005, 5(6) :1347 - 1533. 被引量:1
  • 6Margreiter R, Klempnauer J, Neuhausc P, et al. Alemtuzumab ( Campath-1 H) and tacrolimus monotherapy after renal transplantation : results of a prospective randomized trial [J]. Am J Transplant,2008,8 (7) : 1480 - 1485. 被引量:1
  • 7Shapiro R, Alemtuzumab: A new player in induction therapy in renal transplantation [ M/OL]. http://www, medscape, com/ transplantation. 2008,6. 被引量:1
  • 8Tan HP, Kaczorowski OJ, Basu M, et al. Tacrolimus monotherapy effective after living kidney donor transplant [ J ]. Am Transplant Congress, 2008,3 : 2 - 4. 被引量:1
  • 9Gruessner RW, Kandaswamy R, Humar A, et al. Calcineurin inhibitor and steroid - free immunosuppression in pancreas-kidney and solitary pancreas transplantation[J].Transplantation, 2005, 79(9) :1184 - 1189. 被引量:1
  • 10Thai NL, Khan A, Tom K, et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation : one-and two-year outcomes[J]. Transplantation,2006,82 (12) : 1621 - 1624. 被引量:1

共引文献32

同被引文献11

  • 1van den Hoogen MW, Hilbrands LB. Use of monoelonal antibodies in renal transplantation. Immunotherapy, 2011, 3 (7) : 871-880. 被引量:1
  • 2Gabardi S, Martin ST, Roberts KL, et al. Induction immunosuppressive therapies in renal transplantation. Am J Health Syst Pharm, 2011, 68(3): 211-218. 被引量:1
  • 3Bloom DD, Hu H, Fechner JH, et al. T-lymphocyte alloresponses of Campath-lH-treated kiflney transplant patients. Transplantation, 2006, 81 (1) : 81-87. 被引量:1
  • 4Nuekel H, Frey UH, Roth A, et al. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol, 2005, 514(2-3): 217-224. 被引量:1
  • 5Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in P:lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol, 2004, 83 (10) : 634-645. 被引量:1
  • 6Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1 H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet, 1998, 351 (9117): 1701-1702. 被引量:1
  • 7Pondrom S. Alemtuzumab shows promise as off-label induction therapy. Am J Transplant, 2011, 11 (9): 1761- 1762. 被引量:1
  • 8Vincenti F, Pace D, Birnbaum J, et al. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant, 2003, 3(1): 50-52. 被引量:1
  • 9Zhang X, Huang H, Han S, et al. Alemtuzumab induction in renal transplantation: a recta-analysis and systemic review. Transpl Immunol, 2012, 27(2-3): 63-68. . 被引量:1
  • 10Zanfi C, Lauro A, Cescon M, et al. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 4(} recipients during the early postoperative period. Transplant Proc, 2010, 42(1): 35-38. 被引量:1

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部